Jeil Pharmaceutical Co Ltd (271980) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Jeil Pharmaceutical Co Ltd (271980) has a cash flow conversion efficiency ratio of 0.054x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩13.23 Billion ≈ $8.96 Million USD) by net assets (₩243.59 Billion ≈ $165.08 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Jeil Pharmaceutical Co Ltd balance sheet independence to measure how much of total assets are equity-financed.
Jeil Pharmaceutical Co Ltd - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how Jeil Pharmaceutical Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Jeil Pharmaceutical Co Ltd (271980) cash flow quality to evaluate the quality of earnings relative to operating cash generation.
Jeil Pharmaceutical Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Jeil Pharmaceutical Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Charlton Aria Acquisition Corporation Class A Ordinary Shares
NASDAQ:CHAR
|
0.000x |
|
XL Holdings Bhd
KLSE:7121
|
-0.100x |
|
Kokuyo Camlin Limited
NSE:KOKUYOCMLN
|
0.211x |
|
Rithm Property Trust Inc.
NYSE:RPT
|
-0.026x |
|
Sejal Glass Limited
NSE:SEJALLTD
|
0.278x |
|
FitLife Brands, Inc. Common Stock
NASDAQ:FTLF
|
0.088x |
|
OM INFRA LIMITED
NSE:OMINFRAL
|
-0.051x |
|
Envirosuite Ltd
AU:EVS
|
-0.033x |
Annual Cash Flow Conversion Efficiency for Jeil Pharmaceutical Co Ltd (2017–2024)
The table below shows the annual cash flow conversion efficiency of Jeil Pharmaceutical Co Ltd from 2017 to 2024. For the full company profile with market capitalisation and key ratios, see how much is Jeil Pharmaceutical Co Ltd worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩219.32 Billion ≈ $148.63 Million |
₩3.21 Billion ≈ $2.18 Million |
0.015x | +146.19% |
| 2023-12-31 | ₩157.03 Billion ≈ $106.42 Million |
₩-4.98 Billion ≈ $-3.38 Million |
-0.032x | +67.42% |
| 2022-12-31 | ₩155.60 Billion ≈ $105.45 Million |
₩-15.15 Billion ≈ $-10.26 Million |
-0.097x | -185.29% |
| 2021-12-31 | ₩167.35 Billion ≈ $113.41 Million |
₩19.10 Billion ≈ $12.94 Million |
0.114x | +203.36% |
| 2020-12-31 | ₩172.48 Billion ≈ $116.89 Million |
₩-19.05 Billion ≈ $-12.91 Million |
-0.110x | -164.84% |
| 2019-12-31 | ₩170.04 Billion ≈ $115.24 Million |
₩28.96 Billion ≈ $19.62 Million |
0.170x | +46.80% |
| 2018-12-31 | ₩184.93 Billion ≈ $125.33 Million |
₩21.45 Billion ≈ $14.54 Million |
0.116x | +590.46% |
| 2017-12-31 | ₩177.99 Billion ≈ $120.62 Million |
₩-4.21 Billion ≈ $-2.85 Million |
-0.024x | -- |
About Jeil Pharmaceutical Co Ltd
Jeil Pharmaceutical Co.,Ltd develops and supplies pharmaceutical products primarily in South Korea and internationally. It provides products in the areas of antibiotic, gastrointestinal, cardiovascular, neuropsychiatry, oncology, endocrinology, urology, antiviral, and antihistamine. The company exports its products. Jeil Pharmaceutical Co.,Ltd was founded in 1959 and is headquartered in Seoul, So… Read more